The influence of collagen and hyaluronan matrices on the delivery and bioactivity of bone morphogenetic protein-2 and ectopic bone formation
Source abstract
Abstract
Bone morphogenetic protein-2 (BMP-2) is known to enhance fracture healing when delivered via a bovine collagen sponge. However, collagen rapidly releases BMP-2 with a high burst phase that is followed by a low sustained phase. As a result, supra-physiological doses of BMP-2 are often required to successfully treat bone defects. High BMP-2 dosing can introduce serious side effects that include edema, bone overgrowth, cyst-like bone formation and significant inflammation. As the release behavior of BMP-2 carriers significantly affects the efficacy of fracture healing, we sought to compare the influence of two BMP-2 delivery matrices with contrasting release profiles on BMP-2 bioactivity and ectopic bone formation. We compared a thiol-modified hyaluronan (Glycosil™) hydrogel that exhibits a low burst followed by a sustained release of BMP-2 to a collagen sponge for the delivery of three different doses of BMP-2, the bioactivities of released BMP-2 and ectopic bone formation. Analysis of bone formation by micro-computed tomography revealed that low burst followed by sustained release of BMP-2 from a hyaluronan hydrogel induced up to 456% more bone compared to a BMP-2 dose-matched collagen sponge that has a high burst and sustained release. This study demonstrates that BMP-2 released with a low burst followed by a sustained release of BMP-2 is more desirable for bone formation. This highlights the therapeutic potential of hydrogels, particularly hyaluronan-based, for the delivery of BMP-2 for the treatment of bone defects and may help abrogate the adverse clinical effects associated with high dose growth factor use.
Source: europepmc · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Periodontal Regeneration and Treatments · Bone Tissue Engineering Materials · TGF-β signaling in diseases
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (43)
Show source-provided references
1. A comprehensive clinical review of recombinant human bone morphogenetic protein-2 (INFUSE Bone Graft)10.1007/s00264-007-0418-6 ↗
2. Bone morphogenetic proteins and spinal fusion10.3171/foc.2002.13.6.4 ↗
3. Neurologic impairment from ectopic bone in the lumbar canal: a potential complication of off-label PLIF/TLIF use of bone morphogenetic protein-2 (BMP-2)10.1016/j.spinee.2007.06.014 ↗
4. Direct stimulation of osteoclastic bone resorption by bone morphogenetic protein (BMP)-2 and expression of BMP receptors in mature osteoclasts10.1016/S8756-3282(00)00358-6 ↗
5. Collagen sponges for bone regeneration with rhBMP-210.1016/j.addr.2003.08.010 ↗
6. Uludag H, Gao T, Porter TJ, Friess W, Wozney JM. Delivery systems for BMPs: factors contributing to protein retention at an application site. J Bone Joint Surg Am. 2001; 83-A Suppl 1:S128–35.10.2106/00004623-200100002-00007 ↗
7. Bone morphogenetic protein delivery systems10.1097/00007632-200208151-00005 ↗
8. Differential temporal expression of members of the transforming growth factor beta superfamily during murine fracture healing10.1359/jbmr.2002.17.3.513 ↗
9. Recombinant human bone morphogenetic protein-2 in open tibial fractures. A subgroup analysis of data combined from two prospective randomized studies10.2106/JBJS.E.00499 ↗
10. Effect of autologous bone marrow stromal cell seeding and bone morphogenetic protein-2 delivery on ectopic bone formation in a microsphere/poly(propylene fumarate) composite10.1089/ten.tea.2007.0376 ↗
11. Orthotopic bone formation by implantation of apatite-coated poly(lactide-co-glycolide)/hydroxyapatite composite particulates and bone morphogenetic protein-210.1002/jbm.a.31782 ↗
12. Improving bone formation in a rat femur segmental defect by controlling bone morphogenetic protein-2 release10.1089/ten.tea.2010.0446 ↗
13. Bone morphogenetic protein 2 induces pulmonary angiogenesis via Wnt-beta-catenin and Wnt-RhoA-Rac1 pathways10.1083/jcb.200806049 ↗
14. Bone morphogenetic proteins in human bone regeneration10.1530/eje.0.1420009 ↗
15. Global gene profiling reveals a downregulation of BMP gene expression in experimental atrophic nonunions compared to standard healing fractures10.1002/jor.20182 ↗
16. Delivering on the promise of bone morphogenetic proteins10.1016/S0167-7799(01)01665-1 ↗
17. Delivery of recombinant bone morphogenetic proteins for bone regeneration and repair. Part B: delivery systems for BMPs in orthopaedic and craniofacial tissue engineering10.1007/s10529-009-0100-8 ↗
18. Delivery of recombinant bone morphogenetic proteins for bone regeneration and repair. Part A: current challenges in BMP delivery10.1007/s10529-009-0099-x ↗
19. Hyaluronan: its nature, distribution, functions and turnover10.1046/j.1365-2796.1997.00170.x ↗
20. Hyaluronans in the treatment of osteoarthritis of the knee: evidence for disease-modifying activity10.1016/j.joca.2004.11.010 ↗
21. Injectable glycosaminoglycan hydrogels for controlled release of human basic fibroblast growth factor10.1016/j.biomaterials.2005.03.012 ↗
22. Stimulation of in vivo angiogenesis by in situ crosslinked, dual growth factor-loaded, glycosaminoglycan hydrogels10.1016/j.biomaterials.2010.02.043 ↗
23. Calcium phosphates compounds in conjunction with hydrogel as carrier for BMP-2: a study on ectopic bone formation in rats10.1016/j.actbio.2011.04.021 ↗
24. Bone reservoir: injectable hyaluronic acid hydrogel for minimal invasive bone augmentation10.1016/j.jconrel.2011.02.003 ↗
25. Layer-by-layer films as a biomimetic reservoir for rhBMP-2 delivery: controlled differentiation of myoblasts to osteoblasts10.1002/smll.200800804 ↗
26. Hyaluronic acid-based hydrogels functionalized with heparin that support controlled release of bioactive BMP-210.1016/j.biomaterials.2012.05.030 ↗
27. Bone morphogenetic protein-2 converts the differentiation pathway of C2C12 myoblasts into the osteoblast lineage10.1083/jcb.127.6.1755 ↗
28. 3D imaging of tissue integration with porous biomaterials10.1016/j.biomaterials.2008.06.018 ↗
29. Burdick JA, Prestwich GD. Hyaluronic acid hydrogels for biomedical applications. Adv Mater. 2011;23:H41–56.10.1002/adma.201003963 ↗
30. Prestwich GD. Hyaluronic acid-based clinical biomaterials derived for cell and molecule delivery in regenerative medicine. J Control Release. 2011; 155:193–99.10.1016/j.jconrel.2011.04.007 ↗
31. Engineering a clinically-useful matrix for cell therapy10.4161/org.6152 ↗
32. Evaluating drug efficacy and toxicology in three dimensions: using synthetic extracellular matrices in drug discovery10.1021/ar7000827 ↗
33. The translational imperative: making cell therapy simple and effective10.1016/j.actbio.2012.06.043 ↗
34. Disulfide cross-linked hyaluronan hydrogels10.1021/bm025603c ↗
35. In situ crosslinkable hyaluronan hydrogels for tissue engineering10.1016/j.biomaterials.2003.08.014 ↗
36. Biocompatibility and stability of disulfide-crosslinked hyaluronan films10.1016/j.biomaterials.2005.01.003 ↗
37. Attachment and spreading of fibroblasts on an RGD peptide-modified injectable hyaluronan hydrogel10.1002/jbm.a.20002 ↗
38. Localized delivery of growth factors for bone repair10.1016/j.ejpb.2004.03.004 ↗
39. Delivery of bone morphogenetic proteins for orthopedic tissue regeneration10.1016/j.cytogfr.2005.05.001 ↗
40. Accelerated repair of cortical bone defects using a synthetic extracellular matrix to deliver human demineralized bone matrix10.1002/jor.20148 ↗
41. Retention and activity of BMP-2 in hyaluronic acid-based scaffolds in vitro10.1002/jbm.10011 ↗
42. Hyaluronic acid-based clinical biomaterials derived for cell and molecule delivery in regenerative medicine10.1016/j.jconrel.2011.04.007 ↗
43. Long-term delivery enhances in vivo osteogenic efficacy of bone morphogenetic protein-2 compared to short-term delivery10.1016/j.bbrc.2008.02.099 ↗